| 产品描述: | FB23-2 是一种有效的、具有选择性的 FTO 的抑制剂,可直接与FTO结合并选择性抑制FTO的 N6-methyladenosine (m6A) 去甲基酶的活性,其IC50值为2.6 μM |
| 靶点: |
FTO(Cell-free assay):2.6 μM;Apoptosis |
| 体外研究: |
FB23-2 directly binds to FTO and selectively inhibits FTO’s m6A demethylase activity. Mimicking FTO depletion, FB23-2 dramatically suppresses proliferation and promotes the differentiation/apoptosis of human acute myeloid leukemia (AML) cell line cells and primary blast AML cells in vitro |
| 体内研究: |
FB23-2 significantly inhibits the progression of human AML cell lines and primary cells in xeno-transplanted mice |
| 细胞实验: |
Cell lines: Leukemia cells NB4, U937, MV4-11, ML-2; MONOMAC6 (ACC-124) cells; 293T cells; The mouse bone marrow cells FLT3ITD/NPM1, MA9 Concentrations: 10 μM, 5 μM Incubation Time: 24 h, 72 h Method: NB4 and MONOMAC6 cells are treated with DMSO or FB23-2 at varying concentrations for 72 h, while MA9 and FLT3/NPM1 primary cells isolated from AML mice, five human AML cell (MA9.3ITD, MA9.3RAS, U937, ML2, and MV4-11), and human primary AML cells are treated with DMSO or 5 μM FB23-2 for 72 h for dot blot assay |
| 动物实验: |
Animal Models: NSGS mice with xeno-transplantation model Dosages: 2 mg/kg Administration: IP |
| 参考文献: |
1. Yue Huang, et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Cancer Cell. 2019 Apr 15;35(4):677-691.e10. |
| 溶解性: |
DMSO : 62.5 mg/mL (159.34 mM; Need ultrasonic) |
| 保存条件: |
2-8℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.549 ml |
12.747 ml |
25.495 ml |
| 5 mM |
0.51 ml |
2.549 ml |
5.099 ml |
| 10 mM |
0.255 ml |
1.275 ml |
2.549 ml |
| 50 mM |
0.051 ml |
0.255 ml |
0.51 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |